IKNA Company Profile and Key Details

IKNA has shown sold momentum, gaining 12.6% over the past week and 18.18% over the past quarter, though year-to-date performance is down -12.8%. Short-term trend indicators are mixed aligned (SMA20 6.76%, SMA50 9.87%, SMA200 -0.45%). The stock’s 14-day RSI is 59.83 (neutral), while the ATR of 0.96 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -26.29% below its high and over 47.32% above its low.

Ikena Oncology, Inc. generated EPS of -$7.65 over the past year. Five-year average earnings growth is -16.81%. Wall Street analysts project EPS growth of 0.0% annually over the next five years. The latest quarter delivered EPS of -$0.53. The next quarter is forecast at -$1.14. Next year's EPS is expected at -$15.67. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $23.00 to $23.00. The high target offers 34.03% upside. The low target suggests 34.03% downside. The mean target is $23.00. This offers 34.03% upside. Ikena Oncology, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 06, 2025, missed forecasts by 308.46%. The prior quarter beat by -57.14%. Over the last six quarters, Apple has recorded several small beats. These include -12.9% in August 08, 2024.

Ikena Oncology, Inc. has 48.26 million shares outstanding. The public float is 13.87 million shares, elevated short interest at 0.34% of float. This equals 130.17 thousand shares. The short ratio is 0.28 days. Institutional investors hold 82.84% of the float. Insiders own 8.0%. Bonita David P holds 2.00 million shares, ORBIMED ADVISORS LLC has 2.00 million shares and OrbiMed Genesis GP LLC has 1.91 million shares.

Ikena Oncology, Inc. (NASDAQ:IKNA) closed at $17.16 USD, gaining $15.79 (1,152.55%) from the previous close of $1.37. The stock is currently mid-range between its 52-week high and low $1.36 and $23.28. With a market capitalization of about $718.82 million, Ikena Oncology, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.50). Key stats such as the average daily volume over the past year has been around 18.00 thousand shares, trading with heavier-than-usual volume. Headquartered in Boston, MA, Ikena Oncology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mark Manfredi, the company employs approximately 10 people and listed since March 26, 2021. Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs.

Ikena Oncology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.66. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Ikena Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -91.9%, with price expected at $1.39 by August 08, 2025, within a range of $1.34 to $1.44 3-Month Outlook: Projected fall of -95.22%, reaching $0.82 by October 23, 2025, with a range of $0.77 to $0.87. 1-Year Outlook: Projected loss of -93.3%, with price at $1.15 by July 24, 2026, within a range of $0.00 to $0.00.

Ikena Oncology, Inc. (NASDAQ:IKNA) shares are down -12.8% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Ikena Oncology, Inc. trading at a premium to the broader market with a P/E of -3632.31. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $18.25, suggesting 6.35% upside. Our AI forecast model points to short-term weakness (-91.9% over two weeks), a medium-term fall (-95.22% over three months), and a longer-term loss (-93.3% over one year), with expected trading ranges indicating moderate volatility.

Ikena Oncology, Inc. trades at a P/E ratio of -3632.31, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1559.96 reflecting a rich premium to book value. The P/FCF stands at -13.8, also below market averages. Compared to sector medians, Ikena Oncology, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.